Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Mohamad Bassam Sonbol

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6931-242X; OpenAlex author ID A5059366804. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 9

  1. Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. Co-author DOI 10.1038/s41598-026-40757-3↗
  2. Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. First author DOI 10.2147/dddt.s559325↗
  3. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  4. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  5. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13717↗
  6. Contemporary Management of Pancreatic Cancer from an Internist Perspective. Last author DOI 10.1016/j.amjmed.2020.11.009↗
  7. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Co-author DOI 10.14309/ctg.0000000000000414↗
  8. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Co-author DOI 10.3389/fonc.2021.794009↗
  9. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1002/cncr.30927↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tanios Bekaii‐Saab · 9 shared papers, 2017–2026 · strength 1.53
  2. Mitesh J. Borad · 7 shared papers, 2017–2026 · strength 1.21
  3. Hani M. Babiker · 4 shared papers, 2021–2026 · strength 0.84
  4. Pedro Luiz Serrano Usón · 4 shared papers, 2021–2026 · strength 0.62
  5. Daniel H. Ahn · 5 shared papers, 2017–2023 · strength 0.55
  6. Jason Scott Starr · 4 shared papers, 2021–2023 · strength 0.55
  7. Cody R. Eslinger · 1 shared paper, 2026 · strength 0.36
  8. Ben George · 1 shared paper, 2026 · strength 0.36
  9. John Andrew Stauffer · 2 shared papers, 2023 · strength 0.33
  10. Kathlen Oliveira Martins Tiede · 1 shared paper, 2026 · strength 0.30
  11. Fernando Moura · 1 shared paper, 2026 · strength 0.30
  12. Umair Majeed · 2 shared papers, 2021–2023 · strength 0.27
  13. Gehan Botrus · 2 shared papers, 2021 · strength 0.21
  14. Kabir Mody · 2 shared papers, 2021 · strength 0.21
  15. Sakti Chakrabarti · 1 shared paper, 2023 · strength 0.17
  16. Aakash P. Desai · 1 shared paper, 2023 · strength 0.17
  17. Tucker W. Coston · 1 shared paper, 2023 · strength 0.17
  18. Wen Wee Ma · 1 shared paper, 2023 · strength 0.17
  19. Robert R. McWilliams · 1 shared paper, 2023 · strength 0.17
  20. Amit Mahipal · 1 shared paper, 2023 · strength 0.17
  21. Christina Sing-Ying Wu · 1 shared paper, 2023 · strength 0.16
  22. Michael Scott Rutenberg · 1 shared paper, 2023 · strength 0.16
  23. Ahmed Elhariri · 1 shared paper, 2023 · strength 0.16
  24. Qurat Ul Ain Riaz Sipra · 1 shared paper, 2021 · strength 0.15
  25. Douglas O. Faigel · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.